Home / Conditions / Chronic Hepatitis C
Chronic Hepatitis C: when insurers say no, reviewers often say yes
In 58 published external-review decisions involving chronic hepatitis c, independent physician reviewers overturned the insurer’s denial 81% of the time.
Published decisions
58
2001–2026
Overturned
81%
47 denials reversed
Most-fought treatments for chronic hepatitis c
What insurers denied — and how those fights ended.
Typical time to a decision
14 days
Most land between 12 and 20 days
Handled as urgent
13.8%
Expedited when a delay would cause harm
Recent direction
Rising
71.9% → 96% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested Harvoni for treatment of her medical condition. Findings: The physician reviewer found that according to joint guidelines issued by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), all patients with chronic hepatitis C should be treated except those with limited life expectancy due to non-liver-related conditions. This applies regardless of fibrosis stage or viral load. Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor. The drug is FDA-indicated for the treatment of chronic hepatitis C genotype 1 infection in adults.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage of Epclusa 400mg-100mg, once daily for 12 weeks and ribavirin 200 mg three times daily for three weeks. Findings: The physician reviewer found that, according to joint guidelines issued by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), all patients with chronic hepatitis C should be treated except those with limited life expectancy due to non-liver-related conditions. All patients should be treated, regardless of fibrosis stage. Per the guidelines, cirrhotic patients are high priority for treatment, and Epclusa for 12 weeks is recommended as first-line therapy for treatment naive, genotype 3 patients.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Technivie (ombitasvir-paritaprevir-ritonavir 12.5 mg/75 mg/50 mg) tablets for 12 weeks. Findings: The physician reviewer found that : According to the most recent joint guidelines issued by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), all patients with chronic hepatitis C should be treated except those with limited life expectancy due to non-liver-related conditions. This applies regardless of fibrosis stage. The guidelines recommend that treatment naive genotype 4 patients should be treated with Technivie and ribavirin for 12 weeks. However, this is recommended as an alternate regimen rather than first-line therapy.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Epclusa with ribavirin 400 mg – 100 mg tablet for 24 weeks. Findings: The physician reviewer found that according to joint guidelines issued by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), all patients with chronic hepatitis C should be treated except those with life expectancy less than 12 months due to non-liver-related conditions. However, the patient has satisfied this recommendation with two treatments, including a failed treatment with Viekira Pak, an NS5A inhibitor.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for chronic hepatitis c was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.